Invitation to US Chinese Anti-Cancer Association Annual Meeting at ASCO 2012

Submitted by admin on Sun, 03/04/2012 - 00:00

US Chinese Anti-Cancer Association Annual Meeting at ASCO 2012
6:30 - 9:00 pm
June 2nd, 2012
Hilton Chicago, 720 South Michigan Avenue, Chicago, Illinois 6060

Dear colleagues,
On behalf of the organizing committee, we would like to cordially invite you to attend the US Chinese Anti-Cancer Association (USCACA) Annual Meeting at ASCO 2012 at 6:30 - 9:00 pm, June 2nd, 2012. The meeting will highlight collaborations between USCACA and the Chinese Society for Clinical Oncology (CSCO), to showcase recent successes, and to explore opportunities in further fostering clinical research and expediting oncology drug development. Your presence and presentation will undoubted enhance its academic content and value.

 

Please kindly RSVP to: 2012conference@usc-aca.org  (RSVP form on page 4)

 

We look forward to hearing from your confirmation.

 

Sincerely yours,


 

Wei Zhang, PhD                                 Li Yan, MD, PhD                      

President                                           Managing Director

 


Michael Shi, MD, PhD,                        Wancai Yang, MD

Co-Chair, Organizing Committee        Co-Chair, Organizing Committee

 

 

 

US Chinese Anti-Cancer Association



 

US Chinese Anti-Cancer Association Annual Meeting

6:30 - 9:00 pm, June 2nd, 2012; Northwest 5, Hilton Chicago, 720 South Michigan Avenue, Chicago, Illinois 60605

 

6:30 - 6:35    Introduction and Welcome ¡§C Dr. Michael Shi, USCACA Annual Meeting Co-Chair

 

6:35 - 6:45    USCACA Presidential Address - Dr. Wei Zhang, President, USCACA

 

6:45 - 7:15     USCACA-CSCO-SFDA New Cancer Drug Development Committee Launch Ceremony - ""Current oncology drug development landscape in China"", Deputy Chief, China SFDA (invited)

                    - Dr. Shu-kui Qing, President, Chinese Society for Clinical Oncology (CSCO)

                    - Dr. Li Yan, Managing Director, USCACA

 

       7:15 ¡§C 8:30   Panel Discussion: Emerging role of China in global clinical development of novel anti-cancer drugs:   

       7:15-7:30 Oncology Drug Early Development Capabilities in China

                            - ""START Shanghai"", Dr. Jin Li, Clinical Director, South Texas Accelerated Research Therapeutics (START) Shanghai; Gina Mangold, Director of Operation, START

                             - ""Oncology Trial Center Jilin"", Dr. Song Li, President, Frontage lab

 

7:30-7:45 Novel NCE development and Partnership with Chinese Companies

- Dr. Susan Galbraith, Head of Oncology Innovative Medicines, AstraZeneca

- Dr. Hua Mu, Sr. VP, Clinical Development, Hutchison MediPharma

- Dr. Lianshan Zhang, President, R&D, Hengrui Pharmaceutical Co.

 

7:45-8:00 Translational Research in China ¡§C CSCO Biomarker & Translational Medicine Committee

                             - Dr. Yi-Long Wu, President-elect, CSCO; President, Guangdong General Hospital

 

8:00¡§C8:30 China Participation in Global Oncology Drug Development

                       - Dr. Pablo Cagnoni, Sr. VP, Oncology Clinical Development, Novartis

                       - Dr. William Hait, Sr. VP, Worldwide Head Oncology, Jassen Pharmaceutical Co.

                      - Dr. Jin Li, Dean of Medical Oncology, Shanghai Tumor Hospital, Fu Dan University

                       - Dr. Eric Rubin, Vice President, Oncology TA Head, Merck

                       - Dr. Jorge Puente, President, Asia Pacific and Canada, Oncology. Pfizer Inc.

                        - Dr. Gerd Stehle, Vice President, Oncology, Boehringer Ingelheim

                        - Dr. Shou-ching Tang, Professor, University of Minnesota

                        - TBD, Millenium Pharmaceutical Co.

 

8:30 ¡§C 8:35    Closing remarks - Dr. Wei Zhang, President, USCACA

 

8:35 - 9:00     Networking Time

 

 

 

 

US Chinese Anti-Cancer Association


 

U.S. Chinese Anti-Cancer Association (USCACAÃÀÖп¹¡ã©Ð­»¨¢) is a non-profit professional organization founded in 2009. With members from academia, industry and government, USCACA facilitates collaboration among cancer research and physicians in the United States and China. Our current focus is on expediting novel cancer drug development by fostering clinical trial networks, sharing best practices and knowledge of clinical trial, and providing education and training opportunities. USCACA collaborates with Chinese Anti-Cancer Association (CACA Öй¨²¿¹¡ã©Ð­»¨¢), Chinese Society for Clinical Oncology, and other professional associations. Our mandate is to improve cancer treatment through research, education, and collaboration.

 

 

USCACA 2011 Annual Conference Organizing Committee

Co-Chair:         Michael Shi, Novartis Oncology               

Co-chair:          Wancai Yang, University of Illinois Chicago

 

Committee Members:

Xiaoxiang Chen, Boehringer-Ingelheim            Siyuan Cheng, UPMC

Jin Li, Shanghai Tumor Hospital                      Tina Li, UC Davis

Roger Luo, Jassen Pharmaceutical Co.            Weimin Qi, Biocare Medical       

Pascal Qian, Pfizer Oncology                          Shu-kui Qin, Nanjing Bayi Hospital                               

Wenru Song, Millenium Pharmaceutical Co.     Dongfeng Tan, MDACC     

Shou-Ching Tang, Univ. Minnesota                 Yunguang Tong, Cedar Sinai Hospital / UCLA     

Li Xu, Pfizer Oncology                                     Yi-Long Wu, Guangdong General Hospital                 

Li Yan, Merck & Co., Inc.                                 Yun Dai, Virginia Commonwealth University

 

 

 

 

 

 

 

 

US Chinese Anti-Cancer Association Annual Meeting

6:30 - 9:00 pm

June 2nd, 2012

Hilton Chicago, 720 South Michigan Avenue, Chicago, Illinois 6060

 

 

R.S.V.P.


Please advice any dietary preferences.

 

 

 

For Name Tag:

 

Your name & title:

 

 

 


Affiliation:

 

 

 

 

 

 


E-mail:      

 



 
Source:: 
Internet
Group: 
Events and Activities